Remdesivir Allocation I FMOLHS

Given the results of the Adaptive COVID-19 Treatment Trial (ACTT) and approval by the FDA's emergency use authorization process, hospitals have been allocated a limited supply of remdesivir. In an effort to standardize delivery and receipt of the medication within FMOLHS hospitals, a proposed criterion for use and administration of the medication has been created. Intra-facility administration will use the pre-existing non-formulary process with pharmacy monitoring and stewardship.

Proposed Criteria for Use of Remdesivir in COVID-19 Patients

I.

Inclusion	**Exclusion**
Admitted >=18 years	Pregnant/Breast Feeding
Positive COVID Test	GFR <30 ml/min or dialysis dependent
Supplemental oxygen	ALT/AST > 5x Normal
Radiograph w/ evidence of pneumonia	Age < 18
<18 years but >=40 kg and >=12 years	Known Hypersensitivity
	*Platelet count less than 50K
	*Bilirubin greater than 2
	*EF less than 10%

*Trial Exclusion Language: Evidence of multiorgan failure including but not limited to coagulopathy (significant thrombocytopenia), hepatic failure (elevated bilirubin) or renal failure (low urine output or estimated glomerular filtration rate[eGFR]< 30mL/min), or significant cardiomyopathy (low cardiac output).
-Recommended further categorization to objective criteria for clarity.

II.

Criteria for Discontinuation (pharmacy monitoring)
Development of ALT levels≥5 upper limit of normal
Development of AST levels≥5 upper limit of normal
Bilirubin >=2
Acute anaphylactic reaction during infusion
Estimated creatinine clearance drops to < 30 ml/min per Cockcroft-Gault

III. **Duration of therapy:** 6 doses over 5 days[2]

References:

1. Adaptive COVID-19 Treatment Trial. (ClinicalTrials.gov Identifier: NCT04280705)
2. Goldman JD, Lye DC et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. NEJM. 27 May 2020. DOI: 10.1056/NEJMoa2015301